Refractory Acute Lymphoblastic Leukemia Recruiting Phase 1 Trials for Palbociclib (DB09073)

Also known as: Acute Lymphoblastic Leukemia, Refractory / Acute, refractory Lymphoblastic Leukemia / Acute, refractory Lymphocytic leukaemia / Acute, refractory Lymphocytic Leukemia / Acute lymphocytic leukemia refractory / Acute, refractory Lymphoblastic Leukaemia / Acute lymphocytic leukaemia refractory / Refractory Acute lymphoblastic leukaemia

IndicationStatusPhase
DBCOND0058624 (Refractory Acute Lymphoblastic Leukemia)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03132454Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory LeukemiaTreatment